Latest News
Here you find the latest news revolving Sensidose.
Sensidose will participate at the BioStock Investor Meeting on March 16
Sensidose will participate at the BioStock Investor Meeting on March 16. The presentation starts at 14:05. Follow the event online here: https://youtu.be/tv-ZDUn3zzI https://youtu.be/tv-ZDUn3zzI #Sensidose #BioStockSWE #investormeeting #LifeSciences
Sensidose signs an agreement with Desitin Arzneimittel GmbH for sales and marketing of Flexilev/Suades in Germany
Sensidose AB (the "Company") has entered into a service agreement with Desitin Arzneimittel GmbH ("Desitin") for the sales and marketing of Flexilev (under the trade name Suades) in Germany. Sensidose and Desitin will share the revenue from the sales. The launch is...
Sensidose is awarded funding from Vinnova (Sweden´s Innovation Agency) to develop a method for objective registration and treatment of opiate-requiring pain conditions
Sensidose receives SEK 1.22 million in grants from Vinnova for industrial research within the call "Innovation projects in companies". The funding aims to support the company's development of measuring physiological reactions to pain to enable improved pain relief and...
Sensidose attended SALSS 2018 – All about Brains
Sensidose participated in the Swedish-American Life Science Summit (SALSS) between the 22nd to 24th of August 2018 in Stockholm, Sweden. The summit is a by-invitation-only conference bringing together some of the most renowned Life Science executives, scientists,...
Sensidose AGM may 29 2018
The Annual General Meeting was held on May 29 at the company's premises in Sollentuna. The chairman of the meeting was elected lawyer Mikael Smedeby from Lindahl's law firm. At the annual meeting, Gunnar Säll, after 5 years as the chairman resigned. Proposed new...
Sensidose strengthens the organization with sales and marketing director
Sensidose has strengthened its market with the employment of Pontus Salomonsson, who takes the role of sales and marketing manager . Pontus comes departed from Grünenthal where he was the head of Parkinson in the Nordic region. Prior to that, he has worked at Lundbeck...